Latest News and Press Releases
Want to stay updated on the latest news?
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): Ordinær generalforsamling i ALK-Abelló A/S finder sted torsdag den 13. marts 2025 kl. 16.00 hos ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm i henhold til vedhæftede...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The...
-
ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør sin årsrapport for 2024 om morgenen onsdag den 19. februar 2025. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to...
-
Finanskalender 2025 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22. januar 2025: Stilleperiode19. februar 2025: Offentliggørelse af årsrapport 202413. marts 2025 kl. 16.00:...
-
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report...
-
ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart...
-
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses...